文献速递糖尿病肥胖与代谢综合征

非诺贝特与2型糖尿病患者死亡及心血管事件降低相关:韩国国民健康保险服务队列10114例结果

Fenofibrate Use Is Associated With Lower Mortality and Fewer Cardiovascular Events in Patients With Diabetes: Results of 10,114 Patients From the Korean National Health Insurance Service Cohort.
PubMed 文献 · Diabetes Care · 2021-06-22

该研究基于韩国国民健康保险服务2003至2014年数据,纳入63,727例40-79岁糖尿病患者,经1:1倾向匹配比较5,057例非诺贝特使用者与5,057例未使用非诺贝特和/或ω-3脂肪酸者。中位随访3年显示,非诺贝特组主要终点(心肌梗死、卒中、经皮冠状动脉血运重建和心源性死亡的复合终点)及心源性死亡、全因死亡、卒中均显著降低。

要点

  • 非诺贝特使用与主要心血管复合终点风险降低相关(HR 0.76)。
  • 非诺贝特组全因死亡风险显著降低(HR 0.437)。
  • 获益在各LDL-C、HDL-C和甘油三酯亚组中一致。

核心结论

  • 在真实世界大型2型糖尿病队列中,非诺贝特使用与较低的总死亡、心源性死亡及心血管事件发生率相关。

研究设计与样本

  • 基于韩国国民健康保险服务2003至2014年数据的 population-based 队列研究。
  • 从63,727例40-79岁糖尿病患者中,经1:1倾向匹配比较5,057例非诺贝特使用者与5,057例未使用非诺贝特和/或ω-3脂肪酸者。
  • 中位随访3年,主要终点为心肌梗死、卒中、经皮冠状动脉血运重建和心源性死亡的复合终点。

主要发现

  • 主要终点在非诺贝特组显著低于未使用非诺贝特和ω-3脂肪酸组(13.4 vs. 15.5/1000人年;HR 0.76;95%CI 0.62-0.94;P=0.010)。
  • 心源性死亡(1.8 vs. 3.1/1000人年;HR 0.59;95%CI 0.352-0.987;P=0.0446)、全因死亡(7.6 vs. 15.3/1000人年;HR 0.437;95%CI 0.340-0.562;P<0.0001)和卒中(6.5 vs. 8.6/1000人年;HR 0.621;95%CI 0.463-0.833;P=0.0015)在非诺贝特组均显著降低。
  • 按非诺贝特使用时长四分位分层,第4分位风险降低(HR 0.347;95%CI 0.226-0.532;P<0.0001)。
  • 亚组分析显示,按LDL-C、HDL-C和甘油三酯水平分类的各亚组中非诺贝特的有利效应保持一致。

临床怎么用

  • 对于2型糖尿病患者,非诺贝特使用可能与降低死亡和心血管事件风险相关,但需结合个体情况评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We investigated the long-term clinical efficacy of fenofibrate use with regard to mortality and cardiovascular outcomes in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: We performed a population-based cohort study using data of the South Korean National Health Insurance Service from 2003 to 2014. Of 63,727 participants with diabetes aged 40-79 years, 5,057 users of fenofibrate only were compared with 5,057 nonusers of fenofibrate and/or omega-3 fatty acid with 1:1 propensity matching. The primary end point was a composite of myocardial infarction, stroke, percutaneous coronary revascularization, and cardiac death for a median of 3 years. RESULTS: The primary end point was significantly lower in fenofibrate users compared with those using neither fenofibrate nor omega-3 fatty acid (13.4 vs. 15.5 per 1,000 person-years; hazard ratio [HR] 0.76; 95% CI 0.62-0.94; P = 0.010). Cardiac death (1.8 vs. 3.1 per 1,000 person-years; HR 0.59; 95% CI 0.352-0.987; P = 0.0446), all-cause death (7.6 vs. 15.3 per 1,000 person-years; HR 0.437; 95% CI 0.340-0.562; P < 0.0001), and stroke (6.5 vs. 8.6 per 1,000 person-years; HR 0.621; 95% CI 0.463-0.833; P = 0.0015) were significantly lower in the fenofibrate group. When the duration of fenofibrate use was stratified by quartile, the risk decreased in quartile 4, with an HR of 0.347 (95% CI 0.226-0.532; P < 0.0001). In subgroup analysis, the favorable effect of fenofibrate was sustained consistently across all subsets of patients, including those classified by LDL cholesterol, HDL cholesterol, and triglyceride levels. CONCLUSIONS: Use of fenofibrate was associated with a lower rate of total and cardiac mortality and cardiovascular events in patients with type 2 diabetes during a 3-year follow-up in real-world large populations.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Jo SH, Nam H, Lee J, et al. Fenofibrate Use Is Associated With Lower Mortality and Fewer Cardiovascular Events in Patients With Diabetes: Results of 10,114 Patients From the Korean National Health Insurance Service Cohort. Diabetes Care. 2021. PMID: 34158362. doi:10.2337/dc20-1533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。